Scientists have made a breakthrough in understanding the cause of a rare childhood muscle cancer, called Rhabdomyosarcoma (RMS).
The discovery could lead to the development of improved therapies to treat the disease and other types of cancer in the future.
Around 60 and 350 new cases of RMS are diagnosed in the UK and Europe/US respectively, each year. Most RMS tumours occur in children younger than 10 years old.
A collaborative study led by scientists from Harvard University and involving experts from the University of Aberdeen, The Institute of Cancer Research, London, and the Swiss Institute of Bioinformatics has revealed for the first time the key role a protein called Yap plays in triggering RMS.
The findings are published today (Thursday July 31) in Cancer Cell.
Dr Annie Tremblay from Harvard University said: “RMS is a muscle cancer that can arise from any skeletal muscles in the body, although approximately 40% of the cases arise in the head and neck regions.
“The current therapies for RMS, although relatively efficient, are very aggressive and drastically alter the quality-of-life of the children who survive. Indeed, most of the survivors will suffer life-altering consequences such as loss of mobility or vision, growth impairment and developmental problems, or the need for life-long hormone replacement therapies.
“We discovered that in cases of the disease, excessive activity of a protein called Yap causes muscle stem cells to permanently divide instead of stopping and becoming normal muscle tissue.
“Yap does that by inhibiting the activity of muscle determination proteins, which are key to the formation of muscle tissue.
“In contrast to normal muscle stem cells, the high Yap muscle stem cells fail to develop into normal muscle tissue and RMS develops as a consequence.”
During normal muscle development, stem cells turn into developmental muscle cells – called myoblasts – that divide, before finally fusing together to form long muscle fibres.
The Yap protein is fundamental to this process, with the myoblasts experiencing a marked increase in its activity during the division stage. Once enough myoblasts are present, Yap gets turned off which allows them to stop dividing and fuse together to form functional muscles.
Findings from the study show that in instances of RMS cancer, the Yap protein remains active – like the accelerator of a car being stuck.
By combining the results from animal models with histological and bioinformatics approaches using human RMS samples, researchers at the University of Aberdeen, the Swiss Institute of Bioinformatics and the ICR additionally showed that Yap is actually hyper-active in a large proportion of human RMS cases.
Dr Henning Wackerhage from the University of Aberdeen’s Institute of Medical Sciences, said: “Our identification of the Yap protein’s crucial role in the development of Rhabdomyosarcoma is the first step on the road towards understanding how we can target this rare disease.
“Our work will now focus on how the Yap protein works in cancer and how its activity can be controlled.
“If we can achieve the inhibition of Yap locally in the tumours, we could cause the cancer to stop and regress by turning the RMS into normal muscle instead. This would most likely produce significantly less side effects than the current therapies.”
“Other research has shown that Yap is active in several other types of cancer including liver and skin cancers. These results could therefore be of wider significance in also enhancing our global understanding of the role of Yap in cancer.”
Dr Janet Shipley, leader of the Sarcoma Molecular Pathology team at the ICR, said: "This study has promising therapeutic implications for targeting YAP1-driven pathways for the treatment of children with RMS. Through our analyses of human tumour samples, we were able to demonstrate that the findings in the mouse model are highly relevant to these cancers in humans."
The three-year study was supported by funding from Aberdeen charity, Friends of Anchor, Sarcoma UK, the Medical Research Council, Cancer Research UK, the Chris Lucas Trust, and Stand Up to Cancer-AACR innovative research programs and the Canadian Institutes of Health Research.